MME
VRTX icon

Meag Munich Ergo’s Vertex Pharmaceuticals VRTX Stock Holding History

Meag Munich Ergo’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$24.1M Buy
+54,104
New +$24.9M 0.68% 51
2023
Q2 		– Sell
-3,448
Closed -$1.09M – 204
2023
Q1 		$1.09M Sell
3,448
-4,202
-55% -$1.26M 0.05% 124
2022
Q4 		$2.21M Sell
7,650
-3,225
-30% -$983K 0.12% 106
2022
Q3 		$3.15M Buy
10,875
+8,760
+414% +$2.52M 0.19% 89
2022
Q2 		$596K Buy
2,115
+455
+27% +$122K 0.04% 169
2022
Q1 		$439K Buy
+1,660
New +$394K 0.03% 174
2021
Q4 		– Sell
-7,177
Closed -$1.3M – 243
2021
Q3 		$1.3M Hold
7,177
– – 0.23% 92
2021
Q2 		$1.45M Sell
7,177
-296
-4% -$61.9K 0.14% 150
2021
Q1 		$1.61M Buy
7,473
+2,658
+55% +$584K 0.16% 136
2020
Q4 		$1.12M Buy
+4,815
New +$1.1M 0.26% 112
2020
Q3 		– Sell
-5,767
Closed -$1.67M – 231
2020
Q2 		$1.67M Buy
+5,767
New +$1.56M 0.31% 86
2020
Q1 		– Sell
-3,960
Closed -$867K – 484
2019
Q4 		$867K Sell
3,960
-12,895
-77% -$2.61M 0.09% 209
2019
Q3 		$2.8M Buy
16,855
+5,402
+47% +$956K 0.14% 163
2019
Q2 		$2.05M Sell
11,453
-1,018
-8% -$178K 0.16% 143
2019
Q1 		$2.27M Buy
12,471
+9,571
+330% +$1.77M 0.19% 122
2018
Q4 		$472K Hold
2,900
– – 0.06% 288
2018
Q3 		$547K Hold
2,900
– – 0.03% 341
2018
Q2 		$432K Hold
2,900
– – 0.03% 338
2018
Q1 		$461K Sell
2,900
-25,647
-90% -$4.19M 0.02% 361
2017
Q4 		$4.34M Buy
+28,547
New +$4.23M 0.17% 162

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Meag Munich Ergo's VRTX Position: Q2 2025 in Review

Meag Munich Ergo opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2025: 54,104 shares worth $24.1M. The stake represents 0.68% of the portfolio and ranks #51 among its holdings. This is a return to the name: Meag Munich Ergo previously reported a position in VRTX as recently as Q1 2023.

Meag Munich Ergo first reported a position in VRTX in Q4 2017 and has held it in 20 quarters since. 1,559 funds tracked by Wall St. Rank hold VRTX as of Q2 2025.

  • Meag Munich Ergo held 54,104 shares of Vertex Pharmaceuticals worth $24.1M as of Q2 2025.
  • Vertex Pharmaceuticals was a new Meag Munich Ergo position in Q2 2025.
  • Vertex Pharmaceuticals made up 0.68% of Meag Munich Ergo's portfolio in Q2 2025, its #51 holding.
  • Meag Munich Ergo first reported a position in Vertex Pharmaceuticals in Q4 2017 and has held it in 20 quarters since.
  • 1,559 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2025.

Based on Meag Munich Ergo's 13F filing for Q2 2025, filed 16 Jul 2025.